Category: Money Tips Date: 2006-06-08
Source: Guangzhou Bandung Author: Huang Yongyao
By the expansion accelerated, the potential diversion of funds interest rate and other factors, coupled with technical adjustments to the needs of this week's Shanghai and Shenzhen cities of the whole is in a state of soft leather, broader market Wednesday showed once more the sharp decline in many stocks decline deeper, but the whole week in terms of Hu Zhi-yang is a cross-reported income, a sharp shrinkage of volume, indicating that the atmosphere of watching the market very strong, a lot of money would prefer not to play Admission of new shares, resulting in a hot market the secondary market, in stark contrast to light. the whole market is softening due to the adjustment of status, so the whole week, in addition to the Olympic concept stocks, "Coal gas" concept stocks and real estate stocks, the vast part of the individual stocks flat, short-term opportunities is extremely difficult to grasp.
Looking ahead, although a lot of short-term technical indicators have been the Department of Exploration in the end, such as DMI in the + DI bottomed recovery, but not at the bottom of ADX slow sync, the show that the soft leather are not yet over, the next afternoon there were still further explore the possibility of 60-day line, individual estimates indicate that the broader market is likely to be proven line of support after 60 days, probably still need a week or so to adjust, and then in August with the introduction of a number of positive factors, the broader market will it be possible to re-up, therefore, In the operation should be watching mainly because the current short-term opportunities is extremely difficult to grasp, as a great fund investors, but also for the third quarter, and investment group co-operation of a preparation for the recent second quarter, the Fund has announced an investment portfolio, Masukura in the second quarter of the stocks most likely will become a focus of the attack after three quarters road map, according to the second quarter of the Fund Masukura the top 5 major industry, and its holdings are mainly wholesale and retail trade, food and beverage, machinery and equipment and instrumentation, pharmaceutical and biological products and integrated classes. According to this analysis of five major industry can be seen, near a couple of months we have focused to recommend the consumption-related stocks, there is no doubt become the new core assets of the institution, of course, because by the end of June to the current time difference, in this 5 Great Masukura industry, which has dramatically pushed up the plate and stocks still need to avoid the other, according to a recent change in fundamentals, including "Coal Gas" and other new energy concept, as well as secondary coal linkage, the power unit under the half-year results are expected to surge, hot weather caused by electricity shortages, we feel that the industry turning point in the second half of the power unit the opportunity worthy of attention. G to focus on individual stocks in the proposed sub-Po (600,351). According to the second quarter, the Fund's investment portfolio shows, pharmaceutical stocks have become the Fund's new Masukura's core assets, and as full circulation era, acquisitions and anti-takeover will be the market's hottest hot spot, but also in the history of Chinese and foreign stock market on the acquisition and anti-takeover market is the most exciting and most popular subjects. The G sub-Po (600,351) Due to the shareholding ratio of the first and second low and the equity ratio between the two is extremely close, the second largest shareholder of only about 12 million yuan to acquire its outstanding shares of capital can sit tight in the first to obtain a controlling shareholder position, showing that it is extremely rare in the cities of Shenzhen and Shanghai, the most M & A value of "shell" resources, in addition, the company is China one of 50 proprietary Chinese medicines, but also the largest penetration preparation production base, has a number of core technologies with independent intellectual property rights and products, which is particularly dramatic, the company's leading product, "baby one Spirit" is the domestic production of patented exclusive brand, annual sales of 55 million paste, the annual output value of more than 100 million yuan, up 76.43 percent of its gross margin, but also fully demonstrates the company's very strong profitability and substantial monopoly profits. In recent years, sales of the product has maintained a stable increase of 9%, which also makes the company's operating performance has maintained sustained and rapid growth momentum. Since the company's main profit products Pediatric indigestion medicine Dinggui children is a patent umbilical paste products, to expire in 2013, showing that the unit with the concept of independent innovation of Chinese medicine and the concept of national brands, and in the secondary market on the Shanghai and Shenzhen, with independent innovation capability and national brands, such as traditional Chinese medicine concept stock Yunnanbaiyao and East A donkey-hide gelatin and so has the market to recover by the bar and become a major Niugu. In addition, the company has also set up co-operation, Beijing Medical University, Research Center of Chinese medicine, and with the China Medical University, Beijing Traditional Chinese Medicine Research Institute of Church secondary schools in close co-operation efforts in new product research and development, and establish a good relationship, forming a combination of production and research framework. The company already has 38 national patent product, very strong development potential.
